上海莱士,002252,收入构成,报告日期,2020-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 人血白蛋白,39570,19968,19602,49.54%,22.73% 其他血液制品,36023,5370,30653,85.09%,35.55% 其他(补充),17,-- ,-- ,--,0% 静注人免疫球蛋白,55321,19351,35970,65.02%,41.72% 上海莱士,002252,收入构成,报告日期,2019-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 静注人免疫球蛋白,81004,31694,49310,60.87%,29.74% 人血白蛋白,89318,48298,41020,45.93%,24.74% 其他(补充),23,-- ,-- ,--,0% 其他血液制品,88153,12671,75482,85.63%,45.52% 上海莱士,002252,收入构成,报告日期,2019-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 静丙,40238,14828,25410,63.15%,30.65% 其他血液制品,42339,5554,36785,86.88%,44.37% 白蛋白,47136,26419,20717,43.95%,24.99% 上海莱士,002252,收入构成,报告日期,2018-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他血液制品,50716,6619,44096,86.95%,36.62% 白蛋白,71577,34651,36927,51.59%,30.67% 静丙,58131,18740,39390,67.76%,32.71% 上海莱士,002252,收入构成,报告日期,2018-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 人血白蛋白,41518,20281,21236,51.15%,33.1% 静注人免疫球蛋白,26783,8642,18142,67.74%,28.28% 其他血液制品,27775,2992,24784,89.23%,38.63% 上海莱士,002252,收入构成,报告日期,2017-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他血液制品,43100,5891,37209,86.33%,30.31% 人血白蛋白,81882,40970,40913,49.97%,33.32% 静注人免疫球蛋白,66557,22270,44287,66.54%,36.07% 中药产品及食品,1235,865,370,29.95%,0.3% 上海莱士,002252,收入构成,报告日期,2017-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 中药产品及食品,1235,865,370,29.95%,0.69% 其他血液制品,21656,3587,18069,83.44%,33.48% 静注人免疫球蛋白,27814,9423,18391,66.12%,34.08% 人血白蛋白,36031,18898,17133,47.55%,31.75% 上海莱士,002252,收入构成,报告日期,2016-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),1125,-- ,-- ,--,0% 中药产品及食品,6687,2396,4291,64.17%,2.92% 其他血液制品,49292,8107,41185,83.55%,27.99% 静注人免疫球蛋白,84830,26241,58590,69.07%,39.81% 人血白蛋白,90691,47597,43093,47.52%,29.28% 上海莱士,002252,收入构成,报告日期,2016-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),87,-- ,-- ,--,0% 中药产品及食品,2713,668,2045,75.39%,3.02% 其他血液制品,30997,4748,26249,84.68%,38.74% 静丙,31460,10177,21283,67.65%,31.41% 白蛋白,38606,20434,18172,47.07%,26.82% 上海莱士,002252,收入构成,报告日期,2015-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),209,-- ,-- ,--,0% 中药产品及食品,5713,2718,2995,52.43%,2.43% 其他血液制品,32880,5859,27022,82.18%,21.9% 静注人免疫球蛋白,80324,24780,55544,69.15%,45.02% 人血白蛋白,82206,44395,37811,46%,30.65% 上海莱士,002252,收入构成,报告日期,2015-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他血液制品,16878,3686,13193,78.16%,26.32% 中药产品及食品,2227,1165,1062,47.7%,2.12% 人血白蛋白,35901,18230,17671,49.22%,35.25% 静注人免疫球蛋白,26560,8360,18200,68.52%,36.31% 其他(补充),93,-- ,-- ,--,0% 上海莱士,002252,收入构成,报告日期,2014-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 中药产品及食品,3559,2019,1540,43.27%,1.87% 其他(补充),265,-- ,-- ,--,0% 静注人免疫球蛋白,39264,9311,29953,76.29%,36.4% 人血白蛋白,50465,31722,18742,37.14%,22.78% 其他血液制品,38421,6363,32058,83.44%,38.96% 上海莱士,002252,收入构成,报告日期,2014-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),24,-- ,-- ,--,0% 中药产品及食品,1265,852,413,32.68%,1.29% 其他血液制品,11857,2042,9815,82.78%,30.63% 静丙,15795,3536,12259,77.61%,38.26% 白蛋白,25271,15720,9551,37.79%,29.81% 上海莱士,002252,收入构成,报告日期,2013-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),-- ,-- ,-- ,--,0% 其他,17286,2393,14893,86.15%,46.38% 静丙,16634,5843,10790,64.87%,33.61% 白蛋白,15716,9292,6424,40.88%,20.01% 上海莱士,002252,收入构成,报告日期,2013-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),-- ,-- ,-- ,--,0% 其他,9213,1325,7888,85.62%,43.86% 静丙,8969,3104,5865,65.39%,32.61% 白蛋白,11269,7036,4233,37.56%,23.54% 上海莱士,002252,收入构成,报告日期,2012-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),6,9,-2,-37.1%,-0.01% 其他,13866,2396,11470,82.72%,28.62% 静注人免疫球蛋白,26942,8404,18538,68.81%,46.26% 人血白蛋白,25454,15388,10066,39.54%,25.12% 上海莱士,002252,收入构成,报告日期,2012-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 凝血因子类及其他,6731,1315,5416,80.47%,21.7% 静注人免疫球蛋白,18697,5775,12922,69.11%,51.78% 人血白蛋白,16598,9980,6618,39.87%,26.52% 上海莱士,002252,收入构成,报告日期,2012-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 白蛋白,11022,6710,4313,39.13%,32.28% 其他(补充),6,-- ,-- ,--,0% 其他,2898,692,2207,76.14%,16.52% 静丙,9822,2980,6842,69.66%,51.21% 上海莱士,002252,收入构成,报告日期,2011-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),7,-- ,-- ,--,0% 其他,8239,1996,6243,75.77%,18.66% 静注人免疫球蛋白,24144,7360,16784,69.52%,50.17% 人血白蛋白,24348,13921,10427,42.82%,31.17% 上海莱士,002252,收入构成,报告日期,2011-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),7,-- ,-- ,--,0% 其他,2199,564,1635,74.34%,12.3% 静注人免疫球蛋白,10302,3077,7225,70.13%,54.34% 人血白蛋白,10136,5701,4435,43.75%,33.36% 上海莱士,002252,收入构成,报告日期,2010-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,7157,1902,5255,73.42%,17.3% 静丙,19280,5456,13824,71.7%,45.51% 白蛋白,21890,10594,11297,51.61%,37.19% 上海莱士,002252,收入构成,报告日期,2010-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,2368,781,1587,67.03%,13.18% 静注人免疫球蛋白,7317,1967,5350,73.11%,44.42% 人血白蛋白,9242,4135,5106,55.25%,42.4% 上海莱士,002252,收入构成,报告日期,2009-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,4925,2573,2353,47.77%,10.56% 静注人免疫球蛋白,15275,5138,10137,66.36%,45.49% 人血白蛋白,18551,8756,9795,52.8%,43.95% 上海莱士,002252,收入构成,报告日期,2009-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,1573,953,620,39.4%,6.53% 静丙,7634,2480,5154,67.51%,54.3% 白蛋白,7056,3337,3719,52.7%,39.17% 上海莱士,002252,收入构成,报告日期,2008-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,2559,1446,1113,43.5%,5.76% 静丙,14049,3702,10346,73.65%,53.49% 白蛋白,14378,6497,7881,54.82%,40.75% 上海莱士,002252,收入构成,报告日期,2008-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,1587,875,712,44.88%,6.34% 静丙,8225,1938,6287,76.44%,55.95% 白蛋白,7845,3609,4237,54%,37.71% 上海莱士,002252,收入构成,报告日期,2007-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,3404,1802,1602,47.07%,9.43% 静丙,10413,3546,6867,65.95%,40.41% 白蛋白,17180,8654,8526,49.63%,50.17% 上海莱士,002252,收入构成,报告日期,2006-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,2931,1785,1146,39.11%,10.98% 静丙,5759,3862,1897,32.94%,18.17% 白蛋白,19175,11777,7399,38.59%,70.86% 上海莱士,002252,收入构成,报告日期,2005-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,3677,2010,1667,45.35%,14.43% 静丙,8655,5995,2659,30.73%,23.02% 白蛋白,17988,10762,7226,40.17%,62.55%